The Global Cellular Health Screening Market is likely to exhibit a strong 8% CAGR between 2017 and 2022, according to Transparency Market Research. The valuation of the cellular health screening is expected to rise from US$2.1 bn to US$3.1 bn over the forecast period.One of the prime drivers for the global cellular health screening market is the growing geriatric population across the world and particularly in developed regions, where the cellular health screening market is likely to receive a dominant share of its demand in the coming years. The geriatric population has become a dominant contributor to the healthcare sector in recent years due to the high disposable income of the geriatric demographic in developed regions and the rising average age of death, which is prolonging the demand for healthcare services from the geriatric demographic. The growing geriatric demographic in regions such as North America and Europe and the steady government support to technologies that improve geriatric care is thus likely to remain a key driver for the global cellular health screening market in the coming years.
The report looks into the performance of the cellular health screening market in North America, Latin America, Europe, Asia Pacific except Japan, Japan, and the Middle East and Africa in order to understand the regional dynamics of the global market. North America is likely to remain the leading contributor to the global cellular health screening market in the coming years due to the steady growth of the healthcare sector in the region. Europe is also likely to exhibit a strong 7.5% CAGR over the 2017-2022 forecast period to rise to a valuation of US$754.8 mn by 2022. The Asia Pacific except Japan market for cellular health screening is a promising regional segment for players looking to dominate the global cellular health screening market in the coming years.
Leading players in the global cellular health screening market include Quest Diagnostics Incorporated, Bio-Reference Laboratories Inc., Cell Science Systems Corporation, Cleveland HeartLab Inc., Genova Diagnostics Inc., Laboratory Corporation of America Holdings, Life Length S.L., and SpectraCell Laboratories Inc.
Report Overview, with TOC –